Dynamics of Trypanosoma cruzi infection in hamsters and novel association with progressive motor dysfunction.

Chagas disease is a zoonosis caused by the protozoan parasite Trypanosoma cruzi. Clinical outcomes range from long-term asymptomatic carriage to cardiac, digestive, neurological and composite presentations that can be fatal in both acute and chronic stages of the disease. Studies of T. cruzi in animal models, principally mice, have informed our understanding of the biological basis of this variability and its relationship to infection and host response dynamics. Hamsters have higher translational value for many human infectious diseases, but they have not been well developed as models of Chagas disease. We transposed a real-time bioluminescence imaging system for T. cruzi infection from mice into female Syrian hamsters (Mesocricetus auratus). This enabled us to study chronic tissue pathology in the context of spatiotemporal infection dynamics. Acute infections were widely disseminated, whereas chronic infections were almost entirely restricted to the skin and subcutaneous adipose tissue. Neither cardiac nor digestive tract disease were reproducible features of the model. Skeletal muscle had only sporadic parasitism in the chronic phase, but nevertheless displayed significant inflammation and fibrosis, features also seen in mouse models. Whereas mice had normal locomotion, all chronically infected hamsters developed hindlimb muscle hypertonia and a gait dysfunction resembling spastic diplegia. With further development, this model may therefore prove valuable in studies of peripheral nervous system involvement in Chagas disease.

Comunicação na transferência de cuidados para realização de exames de imagem na ótica da enfermagem / Communication in the transfer of care for imaging exams from a nursing perspective / Comunicación en la transferencia de cuidados para exámenes por imágenes desde la perspectiva de enfermería

Objetivo:analisar a percepção de profissionais de enfermagem sobre a comunicação entre equipes na transferência de cuidados de pacientes para a realização de exames de imagem. Método:pesquisa exploratório-descritiva, qualitativa, realizada com 43 profissionais de enfermagem de um complexo hospitalar de Porto Alegre, entre junho e agosto de 2021. Os dados foram coletados por entrevista semiestruturada e utilizou-se Análise de Conteúdo de Minayo. Resultados:emergiram três temas: como ocorre o processo de comunicação para a transferência do paciente internado ao setor de exames; as potencialidades e fragilidades deste processo e ferramentas para qualificar a comunicação. O enfermeiro atua como articulador da comunicação, que ora ocorre utilizando ferramentase com etapas verbais/telefônicas. O sistema de notas de transferência, a dupla checagem e o readbackpossuem falhas, por não serem oficializados nem específicos. Conclusões:os profissionais consideram a comunicação verbal como a maior fragilidade e sugerem ferramentas formais para torná-la efetiva.

Objective:to analyze the perception of nursing professionals regarding communication between teams in the transfer of patient care for imaging examinations. Method:exploratory-descriptive research, qualitative, conducted with 43 nursing professionals from a hospital complex in Porto Alegre, between June and August 2021. Data were collected through semi-structured interviews and analyzed using Minayo's Content Analysis. Results: three themes emerged: how the communication process occurs for the transfer of the hospitalized patient to the examination department; the strengths and weaknesses of this process; and tools to enhance communication. The nurse acts as a communication facilitator, sometimes using tools and verbal/phone methods. The transfer note system, double-checking, and read-back have flaws because they are not formalized nor specific. Conclusions: professionals consider verbal communication the major weakness and suggest formal tools to make it more effective

Objetivo: analizar la percepción de profesionales de enfermería sobre la comunicación entre equipos al momento de transferir la atención al paciente para la realización de exámenes de imagen.Método: investigación realizada con 43 profesionales de enfermería de un complejo hospitalario de Porto Alegre, entre junio y agosto de 2021. Entrevistas semiestructuradas ocurrieron y se utilizó el análisis de contenido. Resultados: surgieron tres temas: cómo ocurre el proceso de comunicación para la transferencia delpaciente hospitalizado al departamento de exámenes; las potencialidades y debilidades de este proceso y las herramientas para cualificar la comunicación. El enfermero actúa como articulador de la comunicación, que en ocasiones ocurre mediante herramientasy pasos verbales/telefónicos. El sistema de notas de transferencia, la doble verificación y la relectura tienen fallas, pues no son oficiales ni específicos. Conclusiones: los profesionales consideran la comunicación verbal como la mayor debilidad y sugieren herramientas formales para hacerla efectiva.

Enteric nervous system regeneration and functional cure of experimental digestive Chagas disease with trypanocidal chemotherapy.

Digestive Chagas disease (DCD) is an enteric neuropathy caused by Trypanosoma cruzi infection. There is a lack of evidence on the mechanism of pathogenesis and rationales for treatment. We used a female C3H/HeN mouse model that recapitulates key clinical manifestations to study how infection dynamics shape DCD pathology and the impact of treatment with the front-line, anti-parasitic drug benznidazole. Curative treatment 6 weeks post-infection resulted in sustained recovery of gastrointestinal transit function, whereas treatment failure led to infection relapse and gradual return of DCD symptoms. Neuro/immune gene expression patterns shifted from chronic inflammation to a tissue repair profile after cure, accompanied by increased cellular proliferation, glial cell marker expression and recovery of neuronal density in the myenteric plexus. Delaying treatment until 24 weeks post-infection led to partial reversal of DCD, suggesting the accumulation of permanent tissue damage over the course of chronic infection. Our study shows that murine DCD pathogenesis is sustained by chronic T. cruzi infection and is not an inevitable consequence of acute stage denervation. The risk of irreversible enteric neuromuscular tissue damage and dysfunction developing highlights the importance of prompt diagnosis and treatment. These findings support the concept of treating asymptomatic, T. cruzi-infected individuals with benznidazole to prevent DCD development.

A panel of phenotypically and genotypically diverse bioluminescent:fluorescent Trypanosoma cruzi strains as a resource for Chagas disease research.

Chagas disease is caused by Trypanosoma cruzi, a protozoan parasite that displays considerable genetic diversity. Infections result in a range of pathological outcomes, and different strains can exhibit a wide spectrum of anti-parasitic drug tolerance. The genetic determinants of infectivity, virulence and therapeutic susceptibility remain largely unknown. As experimental tools to address these issues, we have generated a panel of bioluminescent:fluorescent parasite strains that cover the diversity of the T. cruzi species. These reporters allow spatio-temporal infection dynamics in murine models to be monitored in a non-invasive manner by in vivo imaging, provide a capability to detect rare infection foci at single-cell resolution, and represent a valuable resource for investigating virulence and host:parasite interactions at a mechanistic level. Importantly, these parasite reporter strains can also contribute to the Chagas disease drug screening cascade by ensuring that candidate compounds have pan-species in vivo activity prior to being advanced into clinical testing. The parasite strains described in this paper are available on request.

Synthesis and Anti-Chagas Activity Profile of a Redox-Active Lead 3-Benzylmenadione Revealed by High-Content Imaging.

Chagas disease, or American trypanosomiasis, is a neglected tropical disease which is a top priority target of the World Health Organization. The disease, endemic mainly in Latin America, is caused by the protozoan Trypanosoma cruzi and has spread around the globe due to human migration. There are multiple transmission routes, including vectorial, congenital, oral, and iatrogenic. Less than 1% of patients have access to treatment, relying on two old redox-active drugs that show poor pharmacokinetics and severe adverse effects. Hence, the priorities for the next steps of R&D include (i) the discovery of novel drugs/chemical classes, (ii) filling the pipeline with drug candidates that have new mechanisms of action, and (iii) the pressing need for more research and access to new chemical entities. In the present work, we first identified a hit (4a) with a potent anti-T. cruzi activity from a library of 3-benzylmenadiones. We then designed a synthetic strategy to build a library of 49 3-(4-monoamino)benzylmenadione derivatives via reductive amination to obtain diazacyclic benz(o)ylmenadiones. Among them, we identified by high content imaging an anti-amastigote "early lead" 11b (henceforth called cruzidione) revealing optimized pharmacokinetic properties and enhanced specificity. Studies in a yeast model revealed that a cruzidione metabolite, the 3-benzoylmenadione (cruzidione oxide), enters redox cycling with the NADH-dehydrogenase, generating reactive oxygen species, as hypothesized for the early hit (4a).

Short-course combination treatment for experimental chronic Chagas disease.

Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects millions of people in the Americas and across the world, leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ) and nifurtimox, offer limited efficacy and often lead to adverse side effects because of long treatment durations. Better treatment options are therefore urgently required. Here, we describe a pyrrolopyrimidine series, identified through phenotypic screening, that offers an opportunity to improve on current treatments. In vitro cell-based washout assays demonstrate that compounds in the series are incapable of killing all parasites; however, combining these pyrrolopyrimidines with a subefficacious dose of BNZ can clear all parasites in vitro after 5 days. These findings were replicated in a clinically predictive in vivo model of chronic Chagas disease, where 5 days of treatment with the combination was sufficient to prevent parasite relapse. Comprehensive mechanism of action studies, supported by ligand-structure modeling, show that compounds from this pyrrolopyrimidine series inhibit the Qi active site of T. cruzi cytochrome b, part of the cytochrome bc1 complex of the electron transport chain. Knowledge of the molecular target enabled a cascade of assays to be assembled to evaluate selectivity over the human cytochrome b homolog. As a result, a highly selective and efficacious lead compound was identified. The combination of our lead compound with BNZ rapidly clears T. cruzi parasites, both in vitro and in vivo, and shows great potential to overcome key issues associated with currently available treatments.

Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice.

Benznidazole is the front-line drug used to treat infections with Trypanosoma cruzi, the causative agent of Chagas disease. However, for reasons that are unknown, treatment failures are common. When we examined parasites that survived benznidazole treatment in mice using highly sensitive in vivo and ex vivo bioluminescence imaging, we found that recrudescence is not due to persistence of parasites in a specific organ or tissue that preferentially protects them from drug activity. Surviving parasites are widely distributed and located in host cells where the vast majority contained only one or two amastigotes. Therefore, infection relapse does not arise from a small number of intact large nests. Rather, persisters are either survivors of intracellular populations where co-located parasites have been killed, or amastigotes in single/low-level infected cells exist in a state where they are less susceptible to benznidazole. To better assess the nature of parasite persisters, we exposed infected mammalian cell monolayers to a benznidazole regimen that reduces the intracellular amastigote population to <1% of the pre-treatment level. Of host cells that remained infected, as with the situation in vivo, the vast majority contained only one or two surviving intracellular amastigotes. Analysis, based on non-incorporation of the thymidine analogue EdU, revealed these surviving parasites to be in a transient non-replicative state. Furthermore, treatment with benznidazole led to widespread parasite DNA damage. When the small number of parasites which survive in mice after non-curative treatment were assessed using EdU labelling, this revealed that these persisters were also initially non-replicative. A possible explanation could be that triggering of the T. cruzi DNA damage response pathway by the activity of benznidazole metabolites results in exit from the cell cycle as parasites attempt DNA repair, and that metabolic changes associated with non-proliferation act to reduce drug susceptibility. Alternatively, a small percentage of the parasite population may pre-exist in this non-replicative state prior to treatment.

Cardiac Abnormalities in a Predictive Mouse Model of Chagas Disease.

Chronic Chagas cardiomyopathy (CCC) results from infection with the protozoan parasite Trypanosoma cruzi and is a prevalent cause of heart disease in endemic countries. We previously found that cardiac fibrosis can vary widely in C3H/HeN mice chronically infected with T. cruzi JR strain, mirroring the spectrum of heart disease in humans. In this study, we examined functional cardiac abnormalities in this host:parasite combination to determine its potential as an experimental model for CCC. We utilised electrocardiography (ECG) to monitor T. cruzi-infected mice and determine whether ECG markers could be correlated with cardiac function abnormalities. We found that the C3H/HeN:JR combination frequently displayed early onset CCC indicators, such as sinus bradycardia and right bundle branch block, as well as prolonged PQ, PR, RR, ST, and QT intervals in the acute stage. Our model exhibited high levels of cardiac inflammation and enhanced iNOS expression in the acute stage, but denervation did not appear to have a role in pathology. These results demonstrate the potential of the C3H/HeN:JR host:parasite combination as a model for CCC that could be used for screening new compounds targeted at cardiac remodelling and for examining the potential of antiparasitic drugs to prevent or alleviate CCC development and progression.

Bis-6-amidino-benzothiazole Derivative that Cures Experimental Stage 1 African Trypanosomiasis with a Single Dose.

We designed and synthesized a series of symmetric bis-6-amidino-benzothiazole derivatives with aliphatic central units and evaluated their efficacy against bloodstream forms of the African trypanosome Trypanosoma brucei. Of these, a dicationic benzothiazole compound (9a) exhibited sub-nanomolar in vitro potency with remarkable selectivity over mammalian cells (>26,000-fold). Unsubstituted 5-amidine groups and a cyclohexyl spacer were the crucial determinants of trypanocidal activity. In all cases, mice treated with a single dose of 20 mg kg-1 were cured of stage 1 trypanosomiasis. The compound displayed a favorable in vitro ADME profile, with the exception of low membrane permeability. However, we found evidence that uptake by T. brucei is mediated by endocytosis, a process that results in lysosomal sequestration. The compound was also active in low nanomolar concentrations against cultured asexual forms of the malaria parasite Plasmodium falciparum. Therefore, 9a has exquisite cross-species efficacy and represents a lead compound with considerable therapeutic potential.

Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections.

Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo-electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.

Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an In Vivo Model of Trypanosoma cruzi Infection.

Probing multiple proprietary pharmaceutical libraries in parallel via virtual screening allowed rapid expansion of the structure-activity relationship (SAR) around hit compounds with moderate efficacy against Trypanosoma cruzi, the causative agent of Chagas Disease. A potency-improving scaffold hop, followed by elaboration of the SAR via design guided by the output of the phenotypic virtual screening efforts, identified two promising hit compounds 54 and 85, which were profiled further in pharmacokinetic studies and in an in vivo model of T. cruzi infection. Compound 85 demonstrated clear reduction of parasitemia in the in vivo setting, confirming the interest in this series of 2-(pyridin-2-yl)quinazolines as potential anti-trypanosome treatments.

Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure.

BACKGROUND: Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and is a serious public health problem throughout Latin America. With 6 million people infected, there is a major international effort to develop new drugs. In the chronic phase of the disease, the parasite burden is extremely low, infections are highly focal at a tissue/organ level, and bloodstream parasites are only intermittently detectable. As a result, clinical trials are constrained by difficulties associated with determining parasitological cure. Even highly sensitive PCR methodologies can be unreliable, with a tendency to produce "false-cure" readouts. Improved diagnostic techniques and biomarkers for cure are therefore an important medical need. METHODOLOGY/PRINCIPAL FINDINGS: Using an experimental mouse model, we have combined a multiplex assay system and highly sensitive bioluminescence imaging to evaluate serological procedures for diagnosis of T. cruzi infections and confirmation of parasitological cure. We identified a set of three antigens that in the context of the multiplex serology system, provide a rapid, reactive and highly accurate read-out of both acute and chronic T. cruzi infection. In addition, we describe specific antibody responses where down-regulation can be correlated with benznidazole-mediated parasite reduction and others where upregulation is associated with persistent infection. One specific antibody (IBAG39) highly correlated with the bioluminescence flux and represents a promising therapy monitoring biomarker in mice. CONCLUSIONS/SIGNIFICANCE: Robust, high-throughput methodologies for monitoring the efficacy of anti-T. cruzi drug treatment are urgently required. Using our experimental systems, we have identified markers of infection or parasite reduction that merit assessing in a clinical setting for the longitudinal monitoring of drug-treated patients.

Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.

Tuberculosis and parasitic infections continue to impose a significant threat to global public health and economic growth. There is an urgent need to develop new treatments to combat these diseases. Here, we report the in vitro and in vivo profiles of a new bicyclic nitroimidazole subclass, namely, nitroimidazopyrazinones, against mycobacteria and Trypanosoma cruzi. Derivatives with monocyclic side chains were selective against Mycobacterium tuberculosis and were able to reduce the bacterial load when dosed orally in mice. We demonstrated that deazaflavin-dependent nitroreductase (Ddn) could act effectively on nitroimidazopyrazinones, indicating the potential of Ddn as an activating enzyme for these new compounds in M. tuberculosis. Oral administration of compounds with extended biaryl side chains (73 and 74) was effective in suppressing infection in an acute T. cruzi-infected murine model. These findings demonstrate that active nitroimidazopyrazinones have potential to be developed as orally available clinical candidates against both tuberculosis and Chagas disease.

Invariant surface glycoprotein 65 of Trypanosoma brucei is a complement C3 receptor.

African trypanosomes are extracellular pathogens of mammals and are exposed to the adaptive and innate immune systems. Trypanosomes evade the adaptive immune response through antigenic variation, but little is known about how they interact with components of the innate immune response, including complement. Here we demonstrate that an invariant surface glycoprotein, ISG65, is a receptor for complement component 3 (C3). We show how ISG65 binds to the thioester domain of C3b. We also show that C3 contributes to control of trypanosomes during early infection in a mouse model and provide evidence that ISG65 is involved in reducing trypanosome susceptibility to C3-mediated clearance. Deposition of C3b on pathogen surfaces, such as trypanosomes, is a central point in activation of the complement system. In ISG65, trypanosomes have evolved a C3 receptor which diminishes the downstream effects of C3 deposition on the control of infection.

Uso de celulares e infecções relacionadas à assistência à saúde: revisão integrativa / Cell phone use and healthcare-associated infections: integrative review / Uso de teléfonos celulares e infecciones relacionadas con la atención médica: revisión integradora

: Introdução: Os serviços de saúde têm grande preocupação com qualidade de assistência, segurança do paciente e redução da incidência das infecções relacionadas à assistência à saúde, as quais são consideradas eventos adversos e influenciam o aumento da morbimortalidade. A disseminação do uso de celulares é generalizada, e eles têm se tornado ferramentas de trabalho para profissionais de saúde. Por terem uma superfície de contato direto entre as mãos e outros objetos, tornam-se importante fonte de microrganismos dentro dos ambientes hospitalares. Objetivo: Realizar busca de publicações existentes que relacionam o uso de celulares com as infecções relacionadas à assistência à saúde dentro do ambiente hospitalar. Método: Revisão integrativa, com busca em cinco bases de dados, realizada no período entre março e abril de 2021. Resultados: Foram incluídos 17 artigos, publicados na língua inglesa em periódicos internacionais, entre 2016 e 2021. Conclusão: Identificou-se em todos os artigos a ocorrência de contaminação dos celulares. Evidenciou-se também que a descontaminação frequente dos celulares e a higiene das mãos são indicadas para reduzir o risco de infecção.

Introduction: Health services are very concerned with quality of care, patient safety and reduction of the incidence of infections related to health care, which are considered adverse events and influence the increase in morbidity and mortality. The widespread use of cell phones is widespread, and they have become work tools for healthcare professionals. As they have a direct contact surface between hands and other objects, they become an important source of microorganisms within hospital environments. Objective: To conduct a search for existing publications that relate the use of cell phones with infections related to health care within the hospital environment. Method: Integrative review, with a search in five databases, carried out between March and April 2021. Results: 17 articles were included, published in English in international journals, between 2016 and 2021. Conclusion: Identified in all articles the occurrence of cell phone contamination. It was also shown that frequent decontamination of cell phones and hand hygiene are indicated to reduce the risk of infection.

Introducción: Los servicios de salud están muy preocupados por la calidad de la atención, la seguridad del paciente y la reducción de la incidencia de infecciones relacionadas con la atención de la salud (IRAS), que son consideradas eventos adversos e influyen en el aumento de la morbimortalidad. El uso generalizado de los teléfonos celulares está muy extendido y se han convertido en herramientas de trabajo para los profesionales de la salud. Al tener una superficie de contacto directo entre las manos y otros objetos, se convierten en una fuente importante de microorganismos dentro de los ambientes hospitalarios. Objetivo: Realizar una búsqueda de publicaciones existentes que relacionen el uso de teléfonos celulares con IRAS dentro del ámbito hospitalario. Método: Revisión integradora, con búsqueda en cinco bases de datos, realizada entre marzo y abril de 2021. Resultados: se incluyeron 17 artículos, publicados en inglés en revistas internacionales, entre 2016 y 2021. Conclusión: Se identificó la ocurrencia de contaminación de celulares en todos los artículos. También mostraron que la descontaminación frecuente de los teléfonos celulares y la higiene de manos están indicadas para reducir el riesgo de infección

Visitas de enfermagem pré e pósoperatórias: revisão integrativa / Pre- and postoperative nursing visits: comprehensive review / Visitas de enfermería pre y postoperatorias: revisión integrativa

Objetivo: Analisar a produção científica acerca das visitas de Enfermagem pré e pós-operatórias. Método: Revisão integrativa, com buscas nas bases de dados da Biblioteca Virtual em Saúde, Web of Science, SCOPUS, LILACS, CINAHL, PubMed e SciELO. A pergunta de pesquisa foi: "qual é o enfo-que dos artigos científicos que discutem sobre as visitas de Enfermagem pré e pós-operatórias?". Resultados: Identificaram-se nove artigos de publicações recentes, sendo três produzidos e publicados em periódicos internacionais e seis em nacionais. Oito artigos enfocaram a visita pré-operatória e apenas um a pós-operatória. A maioria dos estudos foi classificada com fraco nível de evidência e dois com moderada. Conclusão: A produção científica direciona-se mais para as visitas de Enfermagem no pré-operatório, afirmando que essas diminuem a ansiedade dos pacientes cirúrgicos e ressaltando que, quando não realizadas, interferem diretamente na qualidade da assistência de Enfermagem. Encontram-se, em alguns serviços, dificuldades para a realização das visitas de Enfermagem, seja pela alta demanda de atividades assistenciais e administrativas, seja pela falta de conhecimento dos enfermeiros e de recursos humanos.

Objective: To analyze the scientific production about pre- and postoperative nursing visits. Method: Comprehensive review with searches in the Virtual Health Library, Web of Science, SCOPUS, LILACS, CINAHL, PubMed and SciELO databases. The research question was: "what is the focus of scien-tific articles that discuss pre- and postoperative nursing visits?". Results: Nine recently published articles were identified, three of which were in international journals and six in Brazilian ones. Eight articles focused on the preoperative visit and only one on the postoperative visit. Most studies were classified as having a low level of evidence and two as having a moderate level. Conclusion: Studies on nursing visits are more focused on preoperative visits, finding that they reduce the anxiety of surgical patients and emphasizing that, when not performed, they directly worsen the quality of nursing care. Difficulties in making nursing visits are found in some services, either due to the high demand for care and administrative activities or due to the lack of knowledge of nurses and human resources.

Objetivo: Analizar la producción científica sobre las visitas de enfermería pre y postoperatorias. Método: Revisión integradora, con búsque-das en las bases de datos Biblioteca Virtual en Salud, Web of Science, SCOPUS, LILACS, CINAHL, PubMed, SciELO. La pregunta de investigación fue: ¿Cuál es el enfoque de los artículos científicos que discuten las visitas de enfermería pre y posoperatorias? Resultados: Se identificaron nueve artículos de publicaciones recientes, tres de los cuales fueron producidos y publicados en revistas internacionales y seis nacionales. Ocho artículos se centraron en la visita preoperatoria y solo uno en la visita posoperatoria. La mayoría de los estudios se clasificaron como con un nivel de evidencia débil y dos como moderados. Conclusión: La producción científica está más dirigida a las visitas de enfermería en el período preoperatorio y afirman que esto reduce la ansiedad de los pacientes quirúrgicos y, cuando no se realiza, interfiere directamente con la calidad de los cuidados de enfermería. En algunos servicios se encuentran dificultades para realizar las visitas de enfermería, debido a la alta demanda de actividades asistenciales y administrativas, el desconocimiento de las enfermeras y la falta de recursos humanos.

Image-Based In Vitro Screening Reveals the Trypanostatic Activity of Hydroxymethylnitrofurazone against Trypanosoma cruzi.

Hydroxymethylnitrofurazone (NFOH) is a therapeutic candidate for Chagas disease (CD). It has negligible hepatotoxicity in a murine model compared to the front-line drug benznidazole (BZN). Here, using Trypanosoma cruzi strains that express bioluminescent and/or fluorescent reporter proteins, we further investigated the in vitro and in vivo activity of NFOH to define whether the compound is trypanocidal or trypanostatic. The in vitro activity was assessed by exploiting the fluorescent reporter strain using wash-out assays and real-time microscopy. For animal experimentation, BALB/c mice were inoculated with the bioluminescent reporter strain and assessed by highly sensitive in vivo and ex vivo imaging. Cyclophosphamide treatment was used to promote parasite relapse in the chronic stage of infection. Our data show that NFOH acts by a trypanostatic mechanism, and that it is more active than BZN in vitro against the infectious trypomastigote form of Trypanosoma cruzi. We also found that it is more effective at curing experimental infections in the chronic stage, compared with the acute stage, a feature that it shares with BZN. Therefore, given its reduced toxicity, enhanced anti-trypomastigote activity, and curative properties, NFOH can be considered as a potential therapeutic option for Chagas disease, perhaps in combination with other trypanocidal agents.

Bioluminescent:Fluorescent Trypanosoma cruzi Reporter Strains as Tools for Exploring Chagas Disease Pathogenesis and Drug Activity.

Chagas disease results from infection with the trypanosomatid parasite Trypanosoma cruzi. Progress in developing new drugs has been hampered by the long term and complex nature of the condition and by our limited understanding of parasite biology. Technical difficulties in assessing the parasite burden during the chronic stage of infection have also proven to be a particular challenge. In this context, the development of noninvasive, highly sensitive bioluminescence imaging procedures based on parasites that express a red-shifted luciferase has greatly enhanced our ability to monitor infections in experimental models. Applications of this methodology have led to new insights into tissue tropism and infection dynamics and have been a major driver in drug development. The system has been further modified by the generation of parasite reporter lines that express bioluminescent:fluorescent fusion proteins, an advancement that has allowed chronic infections in mice to be examined at a cellular level. By exploiting bioluminescence, to identify the rare sites of tissue infection, and fluorescence to detect T. cruzi at the level of individual host cells in histological sections, it has been possible to investigate the replication and differentiation status of parasites in vivo and to examine the cellular environment of infection foci. In combination, these data provide a framework for the detailed dissection of disease pathogenesis and drug activity.

Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.

Phenotypic screening of a 900 compound library of antitubercular nitroimidazole derivatives related to pretomanid against the protozoan parasite Trypanosoma cruzi (the causative agent for Chagas disease) identified several structurally diverse hits with an unknown mode of action. Following initial profiling, a first proof-of-concept in vivo study was undertaken, in which once daily oral dosing of a 7-substituted 2-nitroimidazooxazine analogue suppressed blood parasitemia to low or undetectable levels, although sterile cure was not achieved. Limited hit expansion studies alongside counter-screening of new compounds targeted at visceral leishmaniasis laid the foundation for a more in-depth assessment of the best leads, focusing on both drug-like attributes (solubility, metabolic stability and safety) and maximal killing of the parasite in a shorter timeframe. Comparative appraisal of one preferred lead (58) in a chronic infection mouse model, monitored by highly sensitive bioluminescence imaging, provided the first definitive evidence of (partial) curative efficacy with this promising nitroimidazooxazine class.

In Vivo Analysis of Trypanosoma cruzi Persistence Foci at Single-Cell Resolution.

Infections with Trypanosoma cruzi are usually lifelong despite generating a strong adaptive immune response. Identifying the sites of parasite persistence is therefore crucial to understanding how T. cruzi avoids immune-mediated destruction. However, this is a major technical challenge, because the parasite burden during chronic infections is extremely low. Here, we describe an integrated approach involving comprehensive tissue processing, ex vivo imaging, and confocal microscopy, which allowed us to visualize infected host cells in murine tissue with exquisite sensitivity. Using bioluminescence-guided tissue sampling, with a detection level of <20 parasites, we showed that in the colon, smooth muscle myocytes in the circular muscle layer are the most common infected host cell type. Typically, during chronic infections, the entire colon of a mouse contains only a few hundred parasites, often concentrated in a small number of cells each containing >200 parasites, which we term mega-nests. In contrast, during the acute stage, when the total parasite burden is considerably higher and many cells are infected, nests containing >50 parasites are rarely found. In C3H/HeN mice, but not BALB/c mice, we identified skeletal muscle as a major site of persistence during the chronic stage, with most parasites being found in large mega-nests within the muscle fibers. Finally, we report that parasites are also frequently found in the skin during chronic murine infections, often in multiple infection foci. In addition to being a site of parasite persistence, this anatomical reservoir could play an important role in insect-mediated transmission and have implications for drug development.IMPORTANCETrypanosoma cruzi causes Chagas disease, the most important parasitic infection in Latin America. Major pathologies include severe damage to the heart and digestive tract, although symptoms do not usually appear until decades after infection. Research has been hampered by the complex nature of the disease and technical difficulties in locating the extremely low number of parasites. Here, using highly sensitive imaging technology, we reveal the sites of parasite persistence during chronic-stage infections of experimental mice at single-cell resolution. We show that parasites are frequently located in smooth muscle cells in the circular muscle layer of the colon and that skeletal muscle cells and the skin can also be important reservoirs. This information provides a framework for investigating how the parasite is able to survive as a lifelong infection, despite a vigorous immune response. It also informs drug development strategies by identifying tissue sites that must be accessed to achieve a curative outcome.